A 66-year-old woman with type 2 diabetes and hypertension has an A1C of 7.9% despite maximally tolerated metformin. She has established atherosclerotic cardiovascular disease. According to the 2024 Diabetes Canada pharmacologic update, which class of agent should be prioritised as add-on therapy to improve cardiovascular outcomes?